Vor Biopharma Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VOR Nasdaq 2836 www.vorbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vor Biopharma Inc.

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 6:00 am
Getty Images, Torm, and More Stocks See Action From Activist Investors - Jan 2nd, 2026 1:22 pm
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors - Dec 23rd, 2025 2:01 pm
Vor Bio Announces $150 Million Private Placement - Dec 15th, 2025 6:00 am
Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed? - Dec 12th, 2025 1:11 am
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage - Dec 10th, 2025 9:05 am
Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation? - Dec 2nd, 2025 7:08 am
Vor Bio assumed with a Neutral at Wedbush - Nov 26th, 2025 6:41 am
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know - Nov 25th, 2025 10:00 am
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 2:01 pm
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock - Nov 10th, 2025 7:56 pm
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock - Nov 10th, 2025 2:01 pm
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China - Nov 8th, 2025 9:45 am
Vor Bio to Participate in Upcoming Investor Conferences - Nov 7th, 2025 6:00 am
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer - Nov 3rd, 2025 6:00 am
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 31st, 2025 2:30 pm
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data - Oct 29th, 2025 9:01 am
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease - Oct 22nd, 2025 2:30 pm
Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint - Oct 17th, 2025 6:15 am
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025 - Oct 17th, 2025 6:00 am